Abstract

On February 28 the US Food and Drug Administration took the unprecedented step of seizing stocks of Peritrate SA (Warner-Chileott Labs), a sustained-action preparation of pentaerythritol tetranitrate. This was done because the FDA judged advertisements for the drug to be ‘false and misleading’. They implied that the drug increased survival after myocardial infarction by asking ‘Is Peritrate life - sustaining?’, clearly inviting the answer ‘yes’.